17,261 trials
Prostate Cancer
Primary: Efficacy of Satraplatin as Second Line Therapy in Men With CRCP — 4; 6; 3 participants
Melanoma
Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants
Alcohol Dependence
Primary: Percent Change From Baseline in Heavy Drinking Days — -45.63; -39.72; -60.98; -49.88 percent of heavy drinking days
Obstructive Coronary Artery Disease · Coronary Artery Disease
Primary: Correlation Between Plaque Morphology and HDL Functionality — 0.30 beta coefficient
Opioid Dependence
Primary: Percent of Weekly Urine Samples Negative for Opiates — 64.5; 81.3; 71.1; 66.7 percentage of negative urine samples — p=0.48
HCMV Reactivation or HCMV End-Organ Disease
Primary: Number of Participants With "HCMV Prophylaxis Failure" — 16; 10; 10; 21 Participants — p=0.007
Essential Hypertension
Primary: Mean Change of Diastolic Blood Pressure — -10.15; -7.19; -6.70 mmHg — p=<0.05
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 24 — -0.3; 0.8; 0.4; -0.5 Score on scale — p=0.159
Alcoholism · Alcohol Abuse · Smoking
Primary: Percentage of Heavy Drinking Days During the Last 8 Weeks of Treatment — 2.07; 2.25 log transformed percentage of days
Anaemia
Primary: Change From Baseline (CFB) in Hemaglobin (Hgb) at Week 4 — -1.52; -0.29; -0.02; 0.60 grams/deciliter (g/dL)
Primary Open Angle Glaucoma
Primary: Complication Rates — 29; 28 Participants — p=0.7
Breast Cancer
Primary: Number of Participants With Worsening of Musculoskeletal Symptoms (MS) — 23; 18; 24; 18 participants
Cystic Fibrosis
Primary: Number of Participants With Treatment Emergent Adverse Events. — 14; 13; 15; 21 Participants
Metastatic Melanoma · Cutaneous Melanoma
Primary: Median Progression-free Survival (PFS) With 95% Confidence Intervals — 1.93; 2.53 months
Hyperhidrosis
Primary: Posterior Probability That the Response Rate is Greater Than 50% — 1; 0.9997 Posterior Probability